Although FLCs show certain advantages as early risk warning biomarkers, discrepancies in predictive timing have been reported, which may be influenced by multiple factors, including CD4+ T-cell counts, viral load, and lymphoma subtypes. The gene discussed is CD4; the disease is lymphoma.